Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Discord Confidentially Files for U.S. IPO, Signaling Major Milestone 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Lenovo Unveils AI Cloud Gigafactory With NVIDIA and Launches New AI Platform at CES 2026 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
ROCKVILLE, Md., March 15, 2017 -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the Oppenheimer 27th Annual Healthcare Conference. Sucampo’s presentation will occur on Tuesday, March 21, 2017 at 3:20 PM Eastern Time.
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.
The presentation will be webcast live and may be accessed from the Event Calendar page of Sucampo's website at http://www.sucampo.com/investors/events-presentations/. A replay of the webcast will also be available on the Company's website for several days after the live event. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a pipeline of product candidates in clinical development. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the U.K. For more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).
Contact: Sucampo Pharmaceuticals, Inc. Silvia Taylor Senior Vice President, Investor Relations and Corporate Affairs 1-240-223-3718 [email protected]
